Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-selective immuno-oncology therapies for people
living with cancer, today announced the promotion of Martin Huber,
M.D., to president of Xilio. Dr. Huber will remain head of research
and development (R&D).
“I am delighted to announce the promotion of Marty to president
of Xilio,” said René Russo, Pharm.D., chief executive officer of
Xilio. “Marty’s R&D and operational leadership will be
instrumental to the continued growth and evolution of the company
as we seek to advance our tumor-selective immuno-oncology
programs.”
In addition, Paul Clancy has been elected as chair of the board
of directors of Xilio, and Robert Ross, M.D., chief executive
officer of Surface Oncology, Inc., has been appointed as a member
of the company’s board of directors. Mr. Clancy has served on
Xilio’s board of directors since July 2020 and succeeds Dan Lynch,
who previously served as chair and will transition to serving as a
strategic advisor to Xilio.
“Paul has played a significant role on our board over the past
two years, contributing tremendous insights into financial
management and strategic business planning and execution in support
of Xilio’s growth and evolution,” said Dr. Russo. “I am very
pleased that we will continue to benefit from Paul’s deep industry
expertise and leadership, now as chair of the board of directors.
I’d also like to thank Dan for his numerous contributions and
invaluable perspective during a period in which Xilio transitioned
to both a publicly traded and clinical-stage company.”
Dr. Russo continued, “Rob is an accomplished medical oncologist
with extensive experience leading oncology programs from discovery
through the clinic, and we welcome him to the board. Rob’s
experience will be critical as we continue to advance our clinical
programs and seek to leverage our platform to expand our
pipeline.”
Martin Huber, M.D.Martin Huber, M.D., a medical
oncologist by training, brings more than 30 years of experience in
clinical research and oncology drug development. Prior to becoming
president of Xilio, Dr. Huber served as the company’s president of
R&D and chief medical officer. Before Xilio, he served as
senior vice president and chief medical officer at Tesaro, Inc.
before its acquisition by GlaxoSmithKline plc. Prior to Tesaro, he
served as vice president, oncology clinical research at Merck where
he was instrumental in the advancement of Merck’s oncology
programs, serving as program lead for pembrolizumab in non-small
cell lung cancer. Earlier, Dr. Huber served in various roles of
increasing responsibility at Schering-Plough, Hoffman-La Roche, and
Rhone-Poulenc Rorer. Dr. Huber serves as a member of the board of
directors of Mersana Therapeutics, Inc. and Syndax Pharmaceuticals,
Inc. Dr. Huber received a B.S. in biology from Texas Lutheran
College and an M.D. from Baylor College of Medicine. He completed
his medical oncology training at U.T. M.D. Anderson Cancer
Center.
Paul ClancyPaul Clancy has served on Xilio’s
board of directors since July 2020 and brings more than 35 years of
experience in financial management and strategic business planning.
Mr. Clancy most recently served as executive vice president, senior
advisor of Alexion Pharmaceuticals, Inc., and earlier served as
chief financial officer of Alexion. Prior to Alexion, Mr. Clancy
served as the executive vice president and chief financial officer
at Biogen Inc. Before Biogen, Mr. Clancy spent 13 years at PepsiCo
Inc., serving in a variety of finance, strategy, and general
management positions. Mr. Clancy serves as a member of the board of
directors of Agios Pharmaceuticals, Inc., Incyte Corporation, Exact
Sciences Corporation, and Sionna Therapeutics, a private
biotechnology company. Mr. Clancy is a senior visiting lecturer of
finance at Cornell University’s Graduate School of Business. Mr.
Clancy received his B.S. in business administration from Babson
College and an M.B.A. from Columbia Business School.
Robert Ross, M.D.Robert Ross, M.D., is the
chief executive officer and a member of the board of directors of
Surface Oncology, Inc. Dr. Ross previously served as Surface’s
chief medical officer. Before Surface, Dr. Ross served as the head
of oncology at bluebird bio, Inc. and earlier served in roles as
senior vice president of clinical development and pharmacovigilance
and vice president of clinical development. Prior to bluebird bio,
Dr. Ross worked at Genentech and Infinity Pharmaceuticals, Inc. Dr.
Ross was a Fellow in Medical Oncology and a faculty member at the
Dana Farber Cancer Institute (DFCI) from 2003 to 2007, and then he
maintained a clinical practice at DFCI until 2015. Dr. Ross
currently serves on the board of directors of Obsidian
Therapeutics, Inc., a private biotechnology company. Dr. Ross
received a B.S. in biological sciences and a B.A. in philosophy
from Stanford University, an M.S. in medical science from Harvard
Medical School and an M.D. from Columbia University College of
Physicians and Surgeons. He completed his residency training in
Internal Medicine at the University of California, San
Francisco.
About Xilio TherapeuticsXilio Therapeutics is a
clinical-stage biotechnology company focused on harnessing the
immune system to achieve deep and durable clinical responses to
improve the lives of patients with cancer. The company is using its
proprietary geographically precise solutions (GPS) platform to
rapidly engineer novel molecules, including cytokines and other
biologics, that are designed to optimize their therapeutic index.
These molecules are designed to localize activity within the tumor
microenvironment without systemic effect, resulting in the
potential to achieve enhanced anti-tumor activity. Xilio is
building a pipeline of wholly owned, tumor-selective, GPS-enabled
cytokine and checkpoint inhibitor product candidates, including its
clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4
monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as
its earlier pipeline, including XTX301, a tumor-selective IL-12.
For more information, please visit www.xiliotx.com and follow us on
Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding plans, timing and expectations related to advancing
Xilio’s current or future programs or product candidates; plans,
timing and expectations related to expanding Xilio’s pipeline; the
potential benefits of any of Xilio’s current or future product
candidates in treating patients; and Xilio’s strategy, goals and
anticipated financial performance, milestones, business plans and
focus. The words “aim,” “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “seek,” “target” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of important risks,
uncertainties and other factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, risks and uncertainties related to
ongoing and planned research and development activities, including
initiating, conducting or completing preclinical studies and
clinical trials and the timing and results of such preclinical
studies or clinical trials; the delay of any current or planned
preclinical studies or clinical trials or the development of
Xilio’s current or future product candidates; Xilio’s ability to
obtain and maintain sufficient preclinical and clinical supply of
current or future product candidates; Xilio’s advancement of
multiple early-stage programs; Xilio’s ability to successfully
demonstrate the safety and efficacy of its product candidates and
gain approval of its product candidates on a timely basis, if at
all; results from preclinical studies or clinical trials for
Xilio’s product candidates, which may not support further
development of such product candidates; actions of regulatory
agencies, which may affect the initiation, timing and progress of
current or future clinical trials; Xilio’s ability to obtain,
maintain and enforce patent and other intellectual property
protection for current or future product candidates; Xilio’s
ability to obtain and maintain sufficient cash resources to fund
current or future operating expenses and capital expenditure
requirements; the impact of international trade policies on Xilio’s
business, including U.S. and China trade policies; and the impact
of the COVID-19 pandemic on Xilio’s business, operations, strategy,
goals and anticipated milestones. These and other risks and
uncertainties are described in greater detail in the sections
entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s
filings with the U.S. Securities and Exchange Commission (SEC),
including Xilio’s most recent Quarterly Report on Form 10-Q and any
other filings that Xilio has made or may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Xilio’s views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Except as required by law, Xilio explicitly
disclaims any obligation to update any forward-looking
statements.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference in this press
release.
For Investor Inquiries:Melissa Forst Argot
PartnersXilio@argotpartners.com
For Media Inquiries: Julissa VianaVice
President, Corporate
Communicationsmedia@xiliotx.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Apr 2023 to Apr 2024